Celldex has added another round of positive data demonstrating that its brain cancer vaccine rindopepimut--more formally called Rintega and less formally "rindo"--provided a clear though relatively modest average survival benefit for recurrent glioblastoma patients in a Phase II study. And with the initial data set from Phase III looming later in the year, the biotech is carefully moving forward with its ongoing dialogue with regulators to gauge just how receptive they may be to speeding up an approval.
Researchers in Japan have published a study in the journal Science and Technology of Advanced Materials demonstrating greater potential for nanoparticles that can both carry drugs and act as imaging targets to diagnose malignant tumors in the brain.
FDA grants priority review status in first-line glioblastoma for Medtronic, J&J-backed startup Novocure
The FDA has granted priority review status to Novocure's supplemental PMA application for its Optune to treat newly diagnosed glioblastoma in combination with temozolomide chemotherapy. The tumor-treating-fields device is already approved to treat recurrent glioblastoma in adults.
Investigators say that they've identified a pathway that can be used to target brain tumor stem cells, adding to potential therapeutic strategies for the aggressive disease glioblastoma.
It took a while for VBL Therapeutics to actually complete its IPO last year. And this morning it may be wishing it hadn't succeeded as its stock price crashed following the failure of its midstage studies of a new drug for psoriasis and ulcerative colitis.
A team of neurologists at UT Southwestern notes that EGFR is activated when epidermal growth factor (EGF) binds to it, promoting tumor growth and damping down its response to chemo. And they believe they may have found a particular pathway during their research that could prove attractive for developers involved in oncology.
The only FDA-approved, wearable cancer treatment device may expand its reach. A Phase III trial of Optune (NovoTTF-100A System) from Novocure was halted early due to statistically significant efficacy for the device in combination with chemotherapy to treat newly diagnosed glioblastoma patients.
With the expected launch of Northwest Biotherapeutics' dendritic cell-based therapeutic vaccine DCVax-L, the glioblastoma multiforme drug market is expected to grow rapidly, from $305 million in 2012 to $583 million in 2019, according to market research.
Johns Hopkins researchers published a study showing they can use biodegradable nanoparticles to carry DNA to brain cancer cells. The animal study suggests that these vehicles could deliver what they call "death genes" to the cells, treating the cancer while preserving healthy brain cells in the process.
A class of FDA-approved antipsychotic drugs may provide a new approach to treating the most aggressive form of primary brain cancer, glioblastoma.